• Sarepta Therapeutics recently reported mixed progress across its rare disease portfolio, with Duchenne muscular dystrophy gene therapy Elevidys showing signs of near-term stabilization while its emerging siRNA programs gained increased attention from analysts and partners.
• These developments underscore how Sarepta’s future now hinges on regulatory decisions around Elevidys and the maturation of its siRNA pipeline, set against a tougher safety and operational backdrop.
• We’ll now explore how a more gene therapy‑friendly regulatory tone around Elevidys could reshape Sarepta’s existing investment narrative.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Sarepta Therapeutics Investment Narrative Recap

To own Sarepta today, you have to believe that ELEVIDYS can retain regulatory support and patient confidence while the newer siRNA programs grow into a meaningful second pillar. The latest updates point to regulators striking a more gene therapy friendly tone, which supports ELEVIDYS as the key near term catalyst, but safety oversight and site capacity remain the biggest swing factors for Sarepta’s revenue timing and overall risk profile.

The March 2026 Phase 1/2 data for SRP‑1001 and SRP‑1003, showing early biomarker activity and tolerability in rare muscle diseases, looks especially relevant here. As analysts and partners pay closer attention to Sarepta’s siRNA platform, these readouts matter for how investors weigh ELEVIDYS dependent risks against the potential for a broader, RNA based pipeline to contribute to future growth.

Yet in contrast to the promise around ELEVIDYS, heightened regulatory scrutiny after prior safety events is a risk investors should be aware of if...

Sarepta Therapeutics' narrative projects $1.4 billion revenue and $87.3 million earnings by 2029. This requires a 13.3% yearly revenue decline and an approximately $800.7 million earnings increase from -$713.4 million today.

Uncover how Sarepta Therapeutics' forecasts yield a $21.65 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming revenue could fall about 35.9% a year and earnings stay weak, so compared with concerns about tighter ELEVIDYS oversight, they paint a far more pessimistic picture that you may want to weigh against this latest news.

Explore 5 other fair value estimates on Sarepta Therapeutics - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Sarepta Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Sarepta Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sarepta Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.